Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.44 |
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004137 | 0.91 | HSP90AB1 (0.41) | HSP90AA1HSP90AB1 | |
| SCHEMBL3855019 | 0.81 | FGFR1 (0.47) | CDK2CCNE1CDK1CCNB1CYP3A4 | |
| SCHEMBL13714842 | 0.78 | CCNE1 (0.44) | CDK2CCNE1CDK1CCNB1CYP3A4 | |
| SCHEMBL3134817 | 0.77 | HSP90AB1 (0.41) | HSP90AA1HSP90AB1 | |
| SCHEMBL2912674 | 0.74 | CDK1 (0.47) | CDK2CCNE1CDK1CCNB1CYP3A4 | |
| SCHEMBL5720718 | 0.73 | HSP90AB1 (0.43) | HSP90AA1HSP90AB1 | |
| SCHEMBL2911587 | 0.73 | HDAC6 (0.42) | HSP90AA1HSP90AB1 | |
| SCHEMBL2909221 | 0.72 | HPRT1 (0.34) | CDK2CCNE1CDK1CCNB1HSP90AA1 | |
| SCHEMBL2913721 | 0.72 | HSP90AB1 (0.42) | NT5EHSP90AA1HSP90AB1 | |
| SCHEMBL3288147 | 0.72 | CYP3A4 (0.52) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | CDK2 323/4885CCNE1 522/4885CDK1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.